GlassScriptPhysician profile
Bakul T Roy
NPI 1720056849
$1,426.64
in general payments reported to CMS, 2019-2025
23 companies · $532 in 2025
The $532 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $479 · 2020: $92.01 · 2023: $99.00 · 2024: $224 · 2025: $532.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $756 · Education: $99.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $756.49 |
| Education | $99.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $222.07 | 2019-2020 | |
| Novo Nordisk INC | $155.86 | 2025 | Wegovy, Ozempic |
| Boehringer Ingelheim Pharmaceuticals, INC. | $152.17 | 2019-2025 | Jardiance, Synjardy |
| Mylan Specialty L.P. | $137.00 | 2019 | |
| Insmed, INC. | $127.94 | 2023-2024 | Arikayce |
| Exact Sciences Corporation | $118.91 | 2024-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Comsort, INC | $100.00 | 2019 | |
| Pfizer INC. | $66.85 | 2020-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $43.35 | 2025 | Xifaxan |
| Kowa Pharmaceuticals America, INC. | $40.24 | 2025 | Zoryve |
| Abbvie INC. | $39.61 | 2019-2020 | |
| Phathom Pharmaceuticals, INC. | $25.84 | 2025 | Voquezna |
| Globus Medical, INC. | $23.38 | 2025 | Senza |
| Otsuka America Pharmaceutical, INC. | $22.74 | 2024 | Rexulti |
| Janssen Pharmaceuticals, INC | $20.20 | 2024 | Xarelto |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $20.09 | 2025 | |
| Allergan, INC. | $18.26 | 2020 | |
| Astrazeneca Pharmaceuticals LP | $18.15 | 2024 | Airsupra |
| Amgen INC. | $18.03 | 2025 | Repatha, Otezla |
| Baxter Healthcare | $16.54 | 2025 | Hillrom - Monarch Airway Clearance System |
| Lilly USA, LLC | $14.67 | 2024 | Zepbound, Jardiance |
| Amarin Pharma, INC. | $13.68 | 2020 | |
| Nabriva Therapeutics, Plc | $11.06 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bakul Roy listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.